Ching-Yi Lin
Recent Quotes
"STEM has included stricter patient criteria in its Phase 2 dry AMD trial."
—
Ching-Yi Lin, H.C. Wainwright & Co.
(8/7/15)
more >
"In STEM's dry AMD study, both cohorts showed safety and tolerability."
—
Ching-Yi Lin, H.C. Wainwright & Co.
(6/30/15)
more >
"We are initiating STEM with a Buy rating."
—
Ching-Yi Lin, H.C. Wainwright & Co.
(5/18/15)
more >
Due to permission requirements, not all quotes are shown.
